Niagen Bioscience, Inc. — Director's Dealing 2024

Aug 27, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ChromaDex Corp. (CDXC)
CIK: 0001386570
Period of Report: 2024-08-23

Reporting Person: Patrick Kristin (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-08-23	Common Stock	M	3000	$1.64	Acquired	3000	Direct
2024-08-23	Common Stock	M	20000	$1.67	Acquired	23000	Direct
2024-08-23	Common Stock	S	23000	$3.57	Disposed	0	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2024-08-23	Stock Option (right to buy)	$1.64	M	3000	Disposed	2032-06-15	Common Stock (3000)	Direct
2024-08-23	Stock Option (right to buy)	$1.67	M	20000	Disposed	2033-06-14	Common Stock (20000)	Direct

Footnotes

F1: The weighted average sale price for the transaction reported was $3.57, and the range of prices were between $3.52 and $3.64. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.